Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.
KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. The company's mission is to bring innovative treatments to patients suffering from a range of diseases, with a strong focus on hereditary angioedema (HAE) and diabetic macular edema (DME).
KalVista's core business revolves around developing small molecule plasma kallikrein inhibitors. Their product portfolio includes:
- Hereditary Angioedema (HAE) inhibitors: These inhibitors are designed to prevent and treat the debilitating attacks associated with HAE, a disorder characterized by severe swelling in various body parts.
- Diabetic Macular Edema (DME) inhibitors: These inhibitors target plasma kallikrein, which is implicated in the retinal vascular permeability that leads to DME, a common complication of diabetes that can cause vision loss.
The company operates primarily in the United States and has made significant strides in its research and development efforts. Recent achievements include successful clinical trials, strategic partnerships, and securing funding to advance their pipeline projects.
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments. The company prioritizes transparency and regularly updates stakeholders on its progress through press releases and public disclosures.
Investors looking to keep abreast of the latest developments and financial performance of KalVista Pharmaceuticals can find comprehensive updates and reports on their official website and through stock market platforms like StockTitan.
KalVista Pharmaceuticals presented new data on patient perspectives regarding treatment outcome measures from the phase 3 KONFIDENT trial of sebetralstat at the 2022 HAEi Global Leadership Workshop. The research showed a strong patient preference for using the Patient Global Impression of Change (PGI-C) scale as a clinical endpoint, with over 70% favoring it over other scales. Additionally, findings highlighted the significant mental health impacts of hereditary angioedema (HAE) on patients, with many missing important life events due to anxiety linked to their condition.
KalVista Pharmaceuticals (NASDAQ: KALV) is under investigation by Holzer & Holzer, LLC for potential violations of federal securities laws. This follows the termination of its KOMPLETE phase 2 clinical trial for KVD824 on October 4, 2022, due to elevated liver enzymes observed in all treatment groups. This announcement resulted in a drop in the company's stock price. Investors who incurred losses on their KalVista stock are encouraged to contact Holzer & Holzer for legal advice regarding their rights.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the granting of inducement stock options to four newly-hired employees, totaling 18,000 shares. These options, priced at $14.24 per share, correspond to the closing stock price on October 3, 2022. They vest quarterly over four years, contingent upon continued employment. KalVista specializes in developing oral small molecule protease inhibitors targeting unmet medical needs, with ongoing clinical trials for treatments in hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals (NASDAQ: KALV) has terminated the KOMPLETE Phase 2 clinical trial for KVD824 due to observed elevations in liver enzymes among participants. The company confirmed that these findings do not impact the safety profile of Sebetralstat or the ongoing Phase 3 KONFIDENT trial.
KalVista will focus on advancing Sebetralstat towards a planned NDA filing in 2024 and will prioritize its oral Factor XIIa program for hereditary angioedema (HAE) prophylaxis, aiming for a once-daily therapy.
KalVista Pharmaceuticals (NASDAQ: KALV) has announced the acceptance of multiple abstracts for presentation at the HAE International Global Leadership Workshop in Frankfurt, Germany, from October 6-9, 2022. The presentations focus on patient perspectives regarding optimal treatment outcomes for Hereditary Angioedema (HAE), emphasizing its effects on mental health and quality of life. Notable presentations include a poster on optimal outcome measures and a session on the global impact of HAE attacks. Both presentations are scheduled for October 7 from 2:30-3:30 CET.
KalVista Pharmaceuticals (KALV) announced a significant milestone as its KVD824 Phase 2 clinical trial surpassed 50% enrollment, marking a key step in developing a potential oral prophylactic treatment for hereditary angioedema (HAE). The company has also initiated the KONFIDENT-S open label extension study for sebetralstat, aimed at providing detailed safety data and exploring its usage in adolescents. However, KalVista reported no revenue for the first fiscal quarter, with a net loss of $23 million, reflecting increased R&D and G&A expenses. Cash holdings decreased to $142.1 million.
KalVista Pharmaceuticals recently granted inducement stock options to five new employees, totaling 18,000 shares at an exercise price of $16.83 per share, aligning with the company's stock price on the grant date of September 1, 2022. The options will vest over four years, starting with one-fourth on the anniversary of the commencement date. This initiative adheres to Nasdaq Listing Rule 5635(c)(4), reflecting KalVista's focus on growth and talent acquisition in the pharmaceutical sector.
KalVista Pharmaceuticals (KALV) announced the initiation of its KONFIDENT-S open-label extension study, providing an additional two years of treatment with sebetralstat for hereditary angioedema (HAE) patients. This trial is designed to assess long-term safety and efficacy, with a subtrial including adolescents aged 12-17. Data collected will support a planned FDA NDA filing in 2024, following the ongoing Phase 3 KONFIDENT trial expected to conclude in late 2023. The company aims to position sebetralstat as the first oral, on-demand treatment for HAE.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the grant of inducement stock options to a newly hired employee on August 1, 2022. The compensation committee granted options to purchase 7,000 shares at an exercise price of $12.21 per share, equal to the closing price on the grant date. The options vest one-fourth on the one-year anniversary and the remainder monthly over three years, contingent on continued service. This grant aligns with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) announced its participation in the 1st Annual H.C. Wainwright Hereditary Angioedema Conference, set for July 20, 2022, at 12:00 p.m. ET. CEO Andrew Crockett will engage in an expert panel on oral treatments for hereditary angioedema (HAE) at 11:00 a.m. ET. Webcasts of the presentation and panel will be available on the company's website, with an audio archive accessible for 30 days post-event. KalVista focuses on developing small molecule protease inhibitors for HAE and diabetic macular edema.
FAQ
What is the current stock price of KalVista Pharmaceuticals (KALV)?
What is the market cap of KalVista Pharmaceuticals (KALV)?
What does KalVista Pharmaceuticals specialize in?
What diseases does KalVista target with its products?
What is a plasma kallikrein inhibitor?
Where does KalVista Pharmaceuticals operate?
How can investors stay updated on KalVista's progress?
Has KalVista formed any strategic partnerships?
What are KalVista's recent achievements?
What is hereditary angioedema (HAE)?
What is diabetic macular edema (DME)?
What financial condition is KalVista in?
